Health Care Analysis 25 (1):1-20 (2017)

Abstract
This article is about the justifiability of accepting worse cost effectiveness for orphan drugs, that is, treatments for rare diseases, in a publicly financed health care system. Recently, three arguments have been presented that may be used in favour of exceptionally advantageous economic terms for orphan drugs. These arguments share the common feature of all referring to considerations of justice or fairness: the argument of the irrelevance of group size, the argument from the principle of need, and the argument of identifiability. It is argued that all of these arguments fail to support the conclusion that orphan drugs should be subsidized to a larger extent than treatments for common diseases. The argument of the irrelevance fails to distinguish between directly and indirectly relevant considerations of fairness or justice. The recent attempt to revive the moral relevance of identifiability has provided no novel reasons to think that identifiability is morally relevant in itself or due to considerations of fairness and justice. The argument from the principle of need does not fail due to any inherent flaw in the principle as such. Rather, this principle can be interpreted in different ways, and none of these interpretations support exceptionally advantageous terms economically for treating rare diseases specifically. It is concluded that we are awaiting justice based reasons for the preferential treatment of orphan drugs.
Keywords Cost effectiveness  Identifiability  Justice  Orphan drugs  Prioritization  Rare diseases
Categories (categorize this paper)
ISBN(s)
DOI 10.1007/s10728-014-0284-5
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 70,192
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library

References found in this work BETA

Just Health: Meeting Health Needs Fairly.Norman Daniels - 2007 - Cambridge University Press.
Equality and Priority.Derek Parfit - 1997 - Ratio 10 (3):202–221.
Health, Luck, and Justice.Shlomi Segall - 2009 - Princeton University Press.
Why Sufficiency is Not Enough.Paula Casal - 2007 - Ethics 117 (2):296-326.
Inequality.Larry S. Temkin - 1993 - Oxford University Press.

View all 21 references / Add more references

Citations of this work BETA

The Normative Significance of Identifiability.Tomasz Żuradzki - 2019 - Ethics and Information Technology 21 (4):295-305.
Natural and Social Inequality.David Wasserman & Sean Aas - 2016 - Journal of Moral Philosophy 13 (5):576-601.

View all 9 citations / Add more citations

Similar books and articles

Ethical and Social Aspects on Rare Diseases.Dusanka Krajnovic - 2012 - Filozofija I Društvo 23 (4):32-48.
Ethical Issues in Funding Orphan Drug Research and Development.C. A. Gericke - 2005 - Journal of Medical Ethics 31 (3):164-168.
Advance Monopoly Commitment?J. Sonderholm - 2011 - Public Health Ethics 4 (3):297-302.

Analytics

Added to PP index
2014-08-21

Total views
40 ( #283,723 of 2,507,401 )

Recent downloads (6 months)
1 ( #416,983 of 2,507,401 )

How can I increase my downloads?

Downloads

My notes